ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ
ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ
ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ
ΠΡΟΓΡΑΜΜΑ ΜΕΤΑΠΤΥΧΙΑΚΩΝ ΣΠΟΥΔΩΝ
«ΜΕΘΟΔΟΛΟΓΙΑ ΒΙΟΪΑΤΡΙΚΗΣ ΕΡΕΥΝΑΣ,
ΒΙΟΣΤΑΤΙΣΤΙΚΗ ΚΑΙ ΚΛΙΝΙΚΗ ΒΙΟΠΛΗΡΟΦΟΡΙΚΗ»

ΔΙΠΛΩΜΑΤΙΚΗ ΕΡΓΑΣΙΑ

Assessment of the reporting quality of randomised controlled trials for vitamin D supplementation in autoimmune thyroid disorders based on the CONSORT statement

«Αξιολόγηση της αναφερόμενης ποιότητας τυχαιοποιημένων κλινικών μελετών που αφορούν την χορήγηση βιταμίνης D σε αυτοάνοσες θυρεοειδικές παθήσεις σύμφωνα με την έκθεση CONSORT»

Χρήστος Ε. Βρύσης (MD)

Μεταπτυχιακός φοιτητής

Τριμελής συμβουλευτική επιτροπή
Στεφανίδης Ιωάννης (Επιβλέπων Καθηγητής)
Ζιντζαράς Ηλίας
Δοξάνη Χρυσούλα

Λάρισα, 2022

Contents

1.Abstract

Background - Purpose

Randomized controlled trials (RCTs) are the cornerstone of evidence-based medicine, yet their quality is often suboptimal. The Consolidated Standards of Reporting Trials (CONSORT) statement is a list of advice to upgrade the quality of RCTs.
The aim of this study was the assessment of the quality of RCTs for vitamin D supplements in thyroid autoimmunity according to the revised CONSORT 2010 checklist.

Methods

Databases were searched for RCTs involving patients with autoimmune thyroid disorders who received vitamin D supplements published from 2011 to 2021. A list of 37-items was used and adherence ≥75% was considered of optimal quality. The primary outcome was the mean CONSORT adherence of studies. Secondary outcomes were the estimation of compliance per CONSORT item and the examination for possible determinants of the reporting quallity.

Results

Thirteen eligible trials were found. The mean compliance was 61.15% ± 14.86%. Only 3 of the studies (23%) achieved a good reporting quality (≥75%), while 10 (77%) were presented with inadequate reporting (< 75%). Randomization and blinding were mainly badly reported. IF of journal was associated with the reporting quality in the univariate analysis [p = 0.033, OR = 1.65, 95%CI = (1,116, 1,773)]. Sample size (p= 0.067), number of authors (p= 0.118) and number of citations (p=0.125) were marginally not significant. None of the factors showed significant results in multivariate analysis. Reporting quality and IF were strongly positively correlated [Pearson's r = 0,740, p = 0.04].

Conclusion

This study shows that mean CONSORT adherence of RCTs for Vitamin D supplementation in AITDs is moderate, reflecting that study quality and transparency could be improved with better adherence to CONSORT rules.

Keywords CONSORT · Randomized controlled trials · Vitamin D supplementation · Autoimmune thyroid disease · Hashimoto disease · Graves' disease · Postpartum thyroiditis

Περίληψη

Ιστορικό – Σκοπός
Οι τυχαιοποιημένες ελεγχόμενες κλινικές δοκιμές είναι το καλύτερο εργαλείο της τεκμηριωμένης ιατρικής και η αναφορά τους δεν είναι πάντα η ενδεδειγμένη. Η έκθεση CONSORT είναι ένα σύνολο συστάσεων που βασίζεται σε στοιχεία για τη βελτίωση της ποιότητας των τυχαιοποιημένων κλινικών δοκιμών.
Σκοπός αυτής της μελέτης ήταν η αξιολόγηση της ποιότητας των τυχαιοποιημένων κλινικών δοκιμών για τη χορήγηση βιταμίνης D σε αυτοάνοσες διαταραχές του θυρεοειδούς με βάση την έκθεση CONSORT.

Μέθοδοι
Αναζητήθηκαν σε ιατρικές βάσεις δεδομένων τυχαιοποιημένες ελεγχόμενες κλινικές δοκιμές που αφορούσαν ασθενείς που έλαβαν βιταμίνη D για αυτοάνοσες διαταραχές του θυρεοειδούς και οι οποίες δημοσιεύθηκαν από το 2011 έως το 2021. Η ποιότητα της αναφοράς αξιολογήθηκε χρησιμοποιώντας μια λίστα 37 στοιχείων με βάση τις επικαιροποιημένες οδηγίες CONSORT 2010, ενώ η συμμόρφωση ≥75% ορίστηκε ως η βέλτιστη-επαρκής. Ο πρωταρχικός στόχος ήταν να υπολογιστεί η μέση συμμόρφωση σύμφωνα με την έκθεση CONSORT των RCT που αφορούσαν την χορήγηση βιταμίνης D σε αυτοάνοσα θυρεοειδικά νοσήματα. Δευτερεύοντες στόχοι ήταν η εκτίμηση της συμμόρφωσης κάθε απαιτούμενου της έκθεσης CONSORT και η έρευνα για πιθανούς τροποποιητικούς παράγοντες τόσο μονοπαραγοντικά όσο και με την μέθοδο της πολυπαραγοντικής ανάλυσης. Η συμμόρφωση πάνω από το 75% των απαιτούμενων ορίστηκε ως επαρκής – βέλτιστη.

Αποτελέσματα
Βρέθηκαν δεκατρείς (13) κλινικές δοκιμές που πληρούσαν τα κριτήρια επιλογής. Η μέση συμμόρφωση σύφωνα με την έκθεση CONSORT ήταν 61,15% ± 14,86% (τυπική απόκλιση). Μεταξύ των ανακτημένων μελετών, μόνο 3 (23%) πέτυχαν καλή ποιότητα αναφοράς (≥75%), ενώ 10 (77%) παρουσίασαν ανεπαρκή αναφορά (< 75%). Τα απαιτούμενα σε σχέση με την μέθοδο της τυχαιοποίησης και της αδιαφάνειας της διαδικασίας δεν αναφέρθηκαν παρά μόνο σε ελάχιστο βαθμό. Η μονοπαραγοντική ανάλυση αποκάλυψε μια στατιστικά σημαντική συσχέτιση με την ποιότητα αναφοράς: ο δείκτης απήχησης του περιοδικού [p = 0,033, Λ.Π. = 1,65, 95% Δ.Ε. = (0,116, 0,773)]. Το μέγεθος του δείγματος (p= 0,067), ο αριθμός των συγγραφέων (p= 0,118) και ο αριθμός των αναφορών (p=0,125) πλησίασαν περισσότερο να πετύχουν στατιστικά σημαντικά αποτελέσματα. Η λογαριθμική παλινδρόμηση απέτυχε να επιδείξει σημαντική επίδραση για κάθε έναν από τους παράγοντες. Μια πρόσθετη διερευνητική ανάλυση έδειξε σημαντική, ισχυρή, θετική γραμμική συσχέτιση μεταξύ του δείκτη απήχησης και της ποιότητας αναφοράς [Pearson's r = 0,740 p = 0,04].

Συμπέρασμα
Αυτή η μελέτη δείχνει ότι η μέση συμμόρφωση σύμφωνα με την έκθεση CONSORT για τη χορήγηση βιταμίνης D σε αυτοάνοσες διαταραχές του θυρεοειδούς ήταν
μετρίου βαθμού. Η συμμόρφωση με την έκθεση CONSORT μπορεί να βελτιστοποιήσει την ποιότητα των αναφορών και να ενισχύσει την εγκυρότητα της έρευνας.

Λέξεις-κλειδιά CONSORT · Τυχαιοποιημένες ελεγχόμενες κλινικές δοκιμές · Χορήγηση βιταμίνης D · Αυτοάνοσες παθήσεις του θυρεοειδούς · Θυρεοειδίτιδα Hashimoto · Νόσος Graves' · Θυρεοειδίτιδα κύησης

2. Introduction

The prevalence of Autoimmune thyroid diseases (AITDs) is about five percent which renders them the most common among autoimmune disorders with a continuing rise in incidence. The female population is at a greater risk of developing thyroid autoimmunity than men(1). The most common AITDs are Hashimoto thyroiditis (HT), Graves' disease (GD) among the general population and post-partum thyroiditis (PPT) in pregnant women. AITD are caused by multiple factors, involving both environmental and genetic factors(2–4).

Vitamin D is a secosteroidal hormone precursor and has been identified as a key hormone in the musculoskeletal, nervous system and insulin sensitivity(5–7). Several studies have reported a low vitamin D status in AITD, indicating an association between vitamin D deficiency and thyroid autoimmunity(8–13) . On the other hand, a small number of studies, showed no significant association between AITDs and vitamin D deficiency(14–17). These pieces of evidence led several researchers to examine the effectiveness of vitamin D supplementation in the prevention/treatment of this group of conditions(18,19) .The results are conflicting, so the potential of vitamin D in thyroid diseases treatment needs to be clarified.

Double-blind RCTs are considered to be the highest ranked mean of evidence-based medicine and their results are crucial in the formulation of the therapeutic guidelines(20). RCTs represent better the whole strategy and philosophy of the research(21).
Readers have access to a plethora of articles, so there is a need for a tool to assess the guidance of RCTs(22).

In 1996, an international group of experts created the CONSORT (Consolidated Standards of Reporting Trials) Statement(23). Two revisions followed in 2001 and 2010 with detailed explanation and elaboration documents(24,25). This statement is an evidence-based set of advice, including a checklist of 37 items and a flow diagram whose reporting ensures the avoidance of failing to include important information(25). For that reason, an increasing number of journals endorse compliance with the CONSORT statement to improve reporting standards(26).

The quality of RCTs has been investigated in a variety of specialties(27–31). Our team, in a previous study concerning anticoagulant versus antiplatelet medication for venous thromboembolism prophylaxis, the average CONSORT compliance score was found to be 59.69% (38% − 83%). Only one RCT achieved more than 75% of the CONSORT items (83%)(32).

To our knowledge, no published study has evaluated the quality of RCTs for vitamin D supplement in thyroid autoimmunity based on the CONSORT statement. The most recent study published in December 2021 was a meta-analysis focusing on cases of Hashimoto disease and the evaluation was conducted using the Cochrane Collaboration Risk of Bias tool Statistical analysis(19).

The purpose of this study is to evaluate the reporting quality of RCTs for vitamin D supplementation in autoimmune thyroid disorders according to Consort statement covering a period from January 2011, onwards following the release of the updated CONSORT 2010 guidelines in March 2010, until December 31st, 2021.

3. Methods

The current study constitutes an evaluation of the reporting quality of RCTs for vitamin D supplementation in patients with AITDs, based on the CONSORT statement.

3.1. Data sources and search strategies

An electronic structured literature search was organized using the following databases MEDLINE/PubMed, Cochrane library and Google Scholar. We attempted to identify relevant RCTs published within the time period from January 2011 onwards following the release of the updated CONSORT 2010 guidelines in March 2010, until December 31st, 2021.
The implemented combination of the following terms is reproduced:
(((((("Vitamin D"[Mesh] OR "Ergocalciferols"[Mesh] OR "Vitamin D Response Element"[Mesh] OR "Vitamin D-Binding Protein"[Mesh] OR "Vitamin D Deficiency"[Mesh] OR "Receptors, Calcitriol"[Mesh] OR "Vitamin D3 24-Hydroxylase"[Mesh] OR "vitamin D-binding protein-macrophage activating factor" [Supplementary Concept] OR "Cholecalciferol"[Mesh] OR "MED4 protein, human" [Supplementary Concept] OR "vitamin D binding protein 2, primate" [Supplementary Concept] OR "vitamin D binding protein 1, primate" [Supplementary Concept] OR "vitamin D response element-binding protein 2" [Supplementary Concept] OR "vitamin D 1-alpha hydroxylase" [Supplementary Concept] OR "vitamin D3 glucosiduronate" [Supplementary Concept]) OR ("Calcitriol"[Mesh] OR "25-O-ethyl-calcitriol" [Supplementary Concept] OR "22-dehydro-1,25-dihydroxy-24-dihomovitamin D3" [Supplementary Concept] OR "24,24-difluoro-1,25-dihydroxy-26,27-dimethylvitamin D3" [Supplementary Concept] OR "1,25-dihydroxyvitamin D3-23,26-lactol" [Supplementary Concept] OR "Vitamin D supplementation")) AND ("Hashimoto Disease"[Mesh] OR "Hypothyroidism, Autoimmune" [Supplementary Concept])) OR ("Thyroiditis"[Mesh] OR "Postpartum Thyroiditis"[Mesh] OR "Thyroiditis, Autoimmune"[Mesh] OR "Thyroiditis, Chronic" [Supplementary Concept])) OR "Hypothyroidism"[Mesh]) OR ("anti-thyroid autoantibodies" [Supplementary Concept] OR "Autoantibodies"[Mesh] OR Graves' disease OR Hyperthyroidism OR postpartum thyroiditis)

In order to restrict our search in PubMed we used the "Randomized Controlled Trial" filter for study type, the "English" filter for language and lastly the "Humans" species filter.

3.2. Eligibility of studies

Inclusion criteria:

- Published from January 1st 2011 until December 31st, 2021
- Parallel group RCTs
- One group was randomized to receive calcitriol or other Vitamin D analogs
- They recruit patients with autoimmune thyroid disease

Exclusion criteria:

- Non-randomized studies
- Reviews
- Pilot studies
- Non-human studies
- Studies with crossover design
- Economic analyses
- Small pilot studies
- Study protocols
- Articles not in English

3.3. Reporting assessment tool

We used the revised CONSORT checklist, which includes a 37-item questionnaire(25). The CONSORT elaboration and explanation statement was used as guidance for our process(33). CONSORT offers recommendations for each part of an RCT, such as title, introduction, methods, results, discussion or other information, covering all aspects of an optimal clinical trial(34).

The immediate period (until December 31st 2010) following the publication of the latest revision of CONSORT statement (Mar 2010) was not included in the assessment. This decision was made to provide authors with enough time to abide by the revised recommendations.

3.4. Methodological evaluation

During the evaluation process, we reviewed the selected articles one by one according to the revised CONSORT version of 2010. Each item was appraised one of the following scores: ‘yes’ 1 point when adequately reported, ‘no’ or ‘unclear’ 0 points when inadequately reported or absent. When an item was reported in a different section of the trial, it was considered as a positive response. Regarding items on the CONSORT check-list with statements such as "When applicable" (7b), "If done" (11a) or "If relevant" (11b) they were checked as” non-applicable" if the answer was definite yes or no; then the answer of these items was analyzed accordingly. This resulted in a score range from 0 to 37.

Additional information included publication year, journal ranking (5-year IF published in 2020 by Clarivate Analytics via Journal Citation Reports), reporting of funding sources, number of authors, continent of first author, sample size, number of citations.

3.5. Outcome measures and Statistical analysis

We covered the period from January 2011 until December 31st, 2021. It was decided that the rest of 2020 would not be evaluated in order to provide a sufficient time for authors to conform with the newest recommendations. The primary outcome measure was the mean CONSORT adherence of the included RCTs. Compliance above 75% with the CONSORT items was regarded as cut-off(31,32). We also investigated the adherence of each item separately and the existence of possible determinant factors.

All parameters were analyzed as categorical variables: IF (<2,86, ≥ 2,86 based on the median of our sample), sample size (≥82, <82 based on the median of our sample), citations (≥ 5, <5 based on the median of our sample), number of authors (≥7, <7 based on the median of our sample), funding source (yes/no), Covid-19 pandemic (earlier/in the course of). Pearson's chi squared test (or Fisher's exact test) was used for univariate analysis. A relaxed p-value of 0.20 was established arbitrary as a cut-off value in order to enter the binary logistic regression. A strict P-value of 0.05 was set to be important for the multivariate analysis. Odds ratios (ORs), 95% confidence intervals (95% Cls) and P-value are presented. An additional analysis was performed in order to examine a possible linear correlation between IF and reporting quality. SPSS v.28 package was used for statistical analysis.

3.6. Ethical view

No approval from the Ethical committee of the University of Thessaly was sought, since this study analyzed existing data from publicly available sources.

4. Results

Initially, 8196 studies were obtained through the selected databases (Pubmed, Cochrane library and Google scholar). After duplications removed, 6467 records were remained. Following evaluation of title and abstracts, 20 potentially eligible articles were identified. Finally, the full-text of these studies were examined and 13 studies were included in further assessment. Figure 1 describes the five steps of the search strategy in a PRISMA flow diagram.

4.1 CONSORT adherence

The mean compliance to the CONSORT statement for RCTs was calculated at 61.15% with SD = 14.86% (Median = 62%, minimum & maximum adherence were 38% and 86% respectively). Among the studies, only 3 (23%) achieved a good reporting quality (≥75% of the items), while 10 (77%) presented with inadequate reporting (< 75% of the items). The mean proportion of adherence to the CONSORT statement for each study are presented in Table 1 and Figure 2.



Figure 1. Flow diagram

Article	Medical Journal	Year	Mean compliance score (%)
Chahardoli et al.(35)	Hormone and Metabolic Research	2019	62
Nodehi et al.(36)	European Journal of clinical nutrition	2019	65
Anaraki et al.(37)	Journal of research in medical sciences	2017	51
Anaraki et al.(38)	Journal of research in medical sciences	2017	65
Simsek et al.(39)	Journal of research in medical sciences	2016	44
Chaudhary et al.(40)	Indian Journal of endocrinology and metabolism	2016	52
Behera et al.(41)	Nigerian medical journal	2020	38
Laugesen et al.(42)	Endocrine	2019	84
Laugesen et al.(43)	Thyroid	2019	86
Mei et al.(44)	Annals of palliative medicine	2021	57
Knutsen et al.(45)	Journal of the Endocrine Society	2017	76
Purnamasari et al.(46)	Asian Journal of Pharmaceutical and Clinical Research	2017	72
Ucan et al.(47)	International Journal for vitamin and nutrition research	2016	43

Table 1. List of RCTs along with the CONSORT score



Figure 2. Distribution of the total CONSORT scores of the 13 studies

Adherence per CONSORT item was estimated (Table 2, Figure 3). Specially, 5 of the 37 items of the checklist (13.5%) were reported in all (100%) of the articles and only 16 of the 37 items of the checklist (43.2%) were reported by 75% or more of the studies. Among methodological items, randomization process (items 8a and 8b) and blinding (items 10 and 11a) were mainly inadequately reported. In contrast, a structured abstract (item 1b) was reported adequately (77%) among the studies and is considered of crucial importance, taking into account that most readers base their decision to acquire or not a full text on its abstract.

4.2. Determinants of reporting quality

According to univariate analysis high IF of journal was the only with superior statistical significance ($p<0.05$). Large sample size, great number of authors, existence of funding source was all associated with an adequate p-value ($p < 0.20$) in order to enter binary logistic regression. Results are summarized at Table 3.

The four predictors of the univariate analysis were entered into a multivariable model. None of these was associated significantly with adequate reporting. Particularly, the journal impact factor ($p = 0.150$) failed to demonstrate significant effect, whereas the effect of number of citations ($p = 0.650$), sample size ($p = 0.161$) and number of authors ($p=0.892$) persisted inadequately. Results of binary logistic regression are illustrated at Table 4.

Finally, an additional analysis (Figure 4) disovered the occurrence of satisfactory positive linear corellation between reporting quality and IF
[Pearson's correlation ($r = 0.740$, $p =0.004$)].

	Item No	***Checklist item***	***Compliance (%)***
Title and abstract	1a	Identification as a randomised trial in the title	61
	1b	Structured summary of trial design, methods, results, and conclusions	77
Introduction	2a	Scientific background and explanation of rationale	100
	2b	Specific objectives or hypotheses	100
Methods	3a	Description of trial design (such as parallel, factorial) including allocation ratio	92
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	61
	4a	Eligibility criteria for participants	92
	4b	Settings and locations where the data were collected	92
	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	85
	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	85
	6b	Any changes to trial outcomes after the trial commenced, with reasons	31
	7a	How sample size was determined	46

	7b	When applicable, explanation of any interim analyses and stopping guidelines	70
	8a	Method used to generate the random allocation sequence	46
	8b	Type of randomization; details of any restriction (such as blocking and block size)	70
	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	38
	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	7.7
	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	38
	11b	If relevant, description of the similarity of interventions	31
	12a	Statistical methods used to compare groups for primary and secondary outcomes	100
	12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	46
Results	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome	92
	13b	For each group, losses and exclusions after randomization, together with reasons	70
	14a	Dates defining the periods of recruitment and follow-up	77
	14b	Why the trial ended or was stopped	0
	15	A table showing baseline demographic and clinical characteristics for each group	100
	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	85
	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	15
	17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	23
	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	70
	19	All-important harms or unintended effects in each group	23
Discussion	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	92
	21	Generalizability (external validity, applicability) of the trial findings	31
	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	100
Other information	23	Registration number and name of trial registry	70
	24	Where the full trial protocol can be accessed, if available	15
	25	Sources of funding and other support (such as supply of drugs), role of funders	77

Table 2. Adherence per CONSORT item



Figure 3. Graphical presentation of adherence per CONSORT item

Parameter	*OR*	*95% CI*	*P-value*
IF of journal (>2.86=median)	1.65	1.116 - 1.773	0.033
Funding source (yes/no)	2	0.115 - 34.822	0.631
Covid-19 pandemic (earlier/in the course of)	0.8	0.587 - 1.091	0.4
Citations (>5=median)	8	0.459 - 139.290	0.125
Sample size (>82=median)	1.016	0.994 - 1.039	0.067
Number of authors (>7=median)	1.07	0.547 - 2.093	0.118

OR odds ratio, 95% CI 95% confidence interval, IF impact factor

Table 3. Univariate analysis of possible determinants of reporting quality

Parameter	*OR*	*95% CI*	*P-value*
IF of journal	2.500	0.717 - 8.712	.150
Citations	1.127	0.673 - 1.888	.650
Sample size	1.026	0.990 - 1.064	.161
Number of authors	1.069	0.410 - 2.782	.892

OR odds ratio, 95% CI 95% confidence interval, IF impact factor

Table 4. Multivariate analysis of possible determinants of reporting quality



Figure 4. Correlation (scatter-plot) between reporting quality and IF

5. Discussion

5.1 CONSORT adherence

The present study evaluated the reporting quality of RCTs that examined the effect of vitamin D supplement in thyroid autoimmunity according to 2010 CONSORT statement. The conclusion is that the overall CONSORT adherence is far from optimal, with the mean compliance equal to 61.15%. The number and sample size of RCTs based on our subject, is smaller than that of other endocrinological diseases probably due to rising interest of researchers in the last decade. We collected and analyzed 13 articles referring to 1174 randomized participants. Only 3 of these showed compliance above 75%.

Furthermore, 16 of 37 checklist items (43.2%) were addressed by 75% or more. The report of crucial methodological characteristics like randomization (item 9: allocation concealment method – 38%; item 10: implementation – 7.7%) and blinding (item 11a: who was blinded – 38%) was found to be suboptimal. Unclear or absent description of randomization and blinding degrades RCTs due to complicated risk of bias (48). Also, inadequate explanation of adverse effects in their articles (item 19: harms or unintended effects – 23%) will probably misguide the medical approach of the physicians and may even give wrong advice to their patients. Item 14b (Why the trial ended or was stopped – 0%) was the least reported item. On the contrary, it is hopeful that significant items such as trial design (item 3a – 92%) and report of the interventions for each group (item 5 – 85%) achieved a strong representation.

5.2. Determinants of reporting quality

Univariate analysis suggested that larger sample size, higher number of authors, the presence of funding was all associated with a better reporting quality but not statistically significant. Only RCTs of high-ranked medical journals showed superior adherence to the CONSORT statement giving statistically significant results ($p<0.05$) and additionally a strong linear correlation ($r = 0.740$). IF was previously studied and a number of studies demonstrated an important association between IF and reporting quality (28,29,32,34). This is because journals with a higher IF have more strict rules for the publication of studies.

Despite the indications of univariate analysis, logistic regression of possible determining factors cancelled the previous effect of impact factor in the reporting quality of RCTs. In any case, we have to make reference to commercial funding. It is crucial that our study comes in harmony with previous showing non-significant impact in scientific information (28,48–50).

We were unable to identify published studies exploring the effect of Covid-19 pandemic in the quality of RCTs. We hypothesized that due to increased interest of all specialties dealing with pandemic, many issues would be appeared in conduction of studies. In one hand, this study appeared not to be affected by Covid-19 pandemic. On the other hand, this factor may become a significant determinant in future assessments. It is important to highlight that literature search involved three databases: PubMed/ MEDLINE, Cochrane Library and Google scholar creating a source of 8196 studies and increasing the overall

efficacy of search strategy. As is well known, CONSORT statement is free and the methodology of current study is easily accessible.

However, our results must be interpreted with skepticism and some points need to be addressed. Vitamin D supplementation in autoimmune thyroid disorders is not a field well studied by the research community. As a result, the number of RCTs we analyzed, is quiet low. Moreover, articles not published in English or released beyond the time limit were excluded. The researcher was not blinded to journal and all items were rated as equal. So, the methodological analysis becomes more susceptible to subjectivity as certain items like flow diagram, randomization and blinding are more important than others.

6. Conclusion

To the best of our knowledge, the present study is the first to evaluate the reporting quality of RCTs for Vitamin D supplementation in autoimmune thyroid disorders according to 2010 CONSORT statement. The results we obtained were discouraging. It is our feeling that our subject is generally badly reported. Taking into account the controversial role of VitD supplementation on the prevention and/or treatment of AITD and the increasing number of publications, we concluded that the compliance with CONSORT guidelines becomes essential in order to provide more reliable and consistent answers to scientific question.

Funding This study received no funding.

7. References

1. McLeod DSA, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012 Oct 29;42(2):252–65.
2. Zhao R, Zhang W, Ma C, Zhao Y, Xiong R, Wang H, et al. Immunomodulatory Function of Vitamin D and Its Role in Autoimmune Thyroid Disease. Frontiers in immunology. 2021;12:574967.
3. Mele C, Caputo M, Bisceglia A, Samà MT, Zavattaro M, Aimaretti G, et al. Immunomodulatory Effects of Vitamin D in Thyroid Diseases. Nutrients. 2020 May 16;12(5):1444.
4. Cantorna MT. Vitamin D and Autoimmunity: Is Vitamin D Status an Environmental Factor Affecting Autoimmune Disease Prevalence? Proceedings of the Society for Experimental Biology and Medicine. 2000 Mar;223(3):230–3.
5. Gil Á, Plaza-Diaz J, Mesa MD. Vitamin D: Classic and Novel Actions. Annals of nutrition & metabolism. 2018;72(2):87–95.
6. Bellan M, Guzzaloni G, Rinaldi M, Merlotti E, Ferrari C, Tagliaferri A, et al. Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. Cardiovascular Diabetology. 2014 Dec 11;13(1):57.
7. di Somma C, Scarano E, Barrea L, Zhukouskaya V, Savastano S, Mele C, et al. Vitamin D and Neurological Diseases: An Endocrine View. International Journal of Molecular Sciences. 2017 Nov 21;18(11):2482.
8. Gallo D, Mortara L, Gariboldi MB, Cattaneo SAM, Rosetti S, Gentile L, et al. Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review. Journal of Endocrinological Investigation. 2020 Apr 4;43(4):413–29.
9. Kim D. The Role of Vitamin D in Thyroid Diseases. International journal of molecular sciences. 2017 Sep 12;18(9).
10. Kivity S, Agmon-Levin N, Zisappl M, Shapira Y, Nagy E v, Dankó K, et al. Vitamin D and autoimmune thyroid diseases. Cellular & Molecular Immunology. 2011 May 31;8(3):243–7.
11. Muscogiuri G, Mari D, Prolo S, Fatti L, Cantone M, Garagnani P, et al. 25 Hydroxyvitamin D Deficiency and Its Relationship to Autoimmune Thyroid Disease in the Elderly. International Journal of Environmental Research and Public Health. 2016 Aug 26;13(9):850.
12. Shin DY, Kim KJ, Kim D, Hwang S, Lee EJ. Low Serum Vitamin D Is Associated with Anti-Thyroid Peroxidase Antibody in Autoimmune Thyroiditis. Yonsei Medical Journal. 2014;55(2):476.
13. Goswami R, Marwaha RK, Gupta N, Tandon N, Sreenivas V, Tomar N, et al. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: a community-based survey. British Journal of Nutrition. 2009 Feb 10;102(3):382–6.
14. Muscogiuri G, Tirabassi G, Bizzaro G, Orio F, Paschou SA, Vryonidou A, et al. Vitamin D and thyroid disease: to D or not to D? European Journal of Clinical Nutrition. 2015 Mar 17;69(3):291–6.
15. Bizzaro G, Shoenfeld Y. Vitamin D and thyroid autoimmune diseases: the known and the obscure. Immunologic Research. 2015 Feb 18;61(1–2):107–9.

16. Yasmeh J, Farpour F, Rizzo V, Kheradnam S, Sachmechi I. Hashimoto Thyroiditis not Associated with Vitamin D Deficiency. Endocrine Practice. 2016 Jul;22(7):809–13.
17. Effraimidis G, Badenhoop K, Tijssen JGP, Wiersinga WM. Vitamin D deficiency is not associated with early stages of thyroid autoimmunity. European Journal of Endocrinology. 2012 Jul;167(1):43–8.
18. Wang S, Wu Y, Zuo Z, Zhao Y, Wang K. The effect of vitamin D supplementation on thyroid autoantibody levels in the treatment of autoimmune thyroiditis: a systematic review and a meta-analysis. Endocrine. 2018 Mar 31;59(3):499–505.
19. Zhang J, Chen Y, Li H, Li H. Effects of vitamin D on thyroid autoimmunity markers in Hashimoto's thyroiditis: systematic review and meta-analysis. Journal of International Medical Research. 2021 Dec 6;49(12):030006052110606.
20. Bonadonna G, Valagussa P. Influence of clinical trials on current treatment strategy for Hodgkin's disease. International Journal of Radiation Oncology*Biology*Physics. 1990 Jul;19(1):209–18.
21. Stolberg HO, Norman G, Trop I. Randomized Controlled Trials. American Journal of Roentgenology. 2004 Dec;183(6):1539–44.
22. Schulz KF. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA: The Journal of the American Medical Association. 1995 Feb 1;273(5):408–12.
23. Begg C. Improving the Quality of Reporting of Randomized Controlled Trials. JAMA. 1996 Aug 28;276(8):637.
24. Moher D. The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized Trials. JAMA. 2001 Apr 18;285(15):1987.
25. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. International Journal of Surgery. 2012;10(1):28–55.
26. Stevens A, Shamseer L, Weinstein E, Yazdi F, Turner L, Thielman J, et al. Relation of completeness of reporting of health research to journals' endorsement of reporting guidelines: systematic review. BMJ (Clinical research ed). 2014 Jun 25;348:g3804.
27. Rikos D, Dardiotis E, Aloizou A-M, Siokas V, Zintzaras E, Hadjigeorgiou GM. Reporting Quality of Randomized Controlled Trials in Restless Legs Syndrome Based on the CONSORT Statement. Tremor and other hyperkinetic movements (New York, NY). 2019;9.
28. Kodounis M, Liampas IN, Constantinidis TS, Siokas V, Mentis A-FA, Aloizou A-M, et al. Assessment of the reporting quality of double-blind RCTs for ischemic stroke based on the CONSORT statement. Journal of the Neurological Sciences. 2020 Aug;415:116938.
29. Liampas I, Chlinos A, Siokas V, Brotis A, Dardiotis E. Assessment of the reporting quality of RCTs for novel oral anticoagulants in venous thromboembolic disease based on the CONSORT statement. Journal of Thrombosis and Thrombolysis. 2019 Nov 10;48(4):542–53.
30. Elcivan M, Kowark A, Coburn M, Hamou HA, Kremer B, Clusmann H, et al. A Retrospective Analysis of Randomized Controlled Trials on Traumatic Brain Injury: Evaluation of CONSORT Item Adherence. Brain sciences. 2021 Nov 13;11(11).
31. Rikos D, Dardiotis E, Aloizou A-M, Siokas V, Zintzaras E, Hadjigeorgiou GM. Reporting Quality of Randomized Controlled Trials in Restless Legs Syndrome Based on the

CONSORT Statement. Tremor and other hyperkinetic movements (New York, NY). 2019;9.
32. Beneki E, Vrysis C, Zintzaras E, Doxani C. Analysis of the quality of reporting of randomized controlled trials in anticoagulant versus antiplatelet medication for venous thromboembolism prophylaxis as governed by the CONSORT statement. Journal of Thrombosis and Thrombolysis. 2021 Jul 17;52(1):138–47.
33. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, et al. CONSORT for Reporting Randomized Controlled Trials in Journal and Conference Abstracts: Explanation and Elaboration. PLoS Medicine. 2008 Jan 22;5(1):e20.
34. Ziogas DC, Zintzaras E. Analysis of the quality of reporting of randomized controlled trials in acute and chronic myeloid leukemia, and myelodysplastic syndromes as governed by the CONSORT statement. Annals of epidemiology. 2009 Jul;19(7):494–500.
35. Chahardoli R, Saboor-Yaraghi A-A, Amouzegar A, Khalili D, Vakili AZ, Azizi F. Can Supplementation with Vitamin D Modify Thyroid Autoantibodies (Anti-TPO Ab, Anti-Tg Ab) and Thyroid Profile (T3, T4, TSH) in Hashimoto's Thyroiditis? A Double Blind, Randomized Clinical Trial. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2019 May;51(5):296–301.
36. Nodehi M, Ajami A, Izad M, Asgarian Omran H, Chahardoli R, Amouzegar A, et al. Effects of vitamin D supplements on frequency of CD4+ T-cell subsets in women with Hashimoto's thyroiditis: a double-blind placebo-controlled study. European journal of clinical nutrition. 2019;73(9):1236–43.
37. Vahabi Anaraki P, Aminorroaya A, Amini M, Momeni F, Feizi A, Iraj B, et al. Effect of Vitamin D deficiency treatment on thyroid function and autoimmunity markers in Hashimoto's thyroiditis: A double-blind randomized placebo-controlled clinical trial. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2017;22:103.
38. Anaraki PV, Aminorroaya A, Amini M, Feizi A, Iraj B, Tabatabaei A. Effects of Vitamin D deficiency treatment on metabolic markers in Hashimoto thyroiditis patients. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2017;22:5.
39. Simsek Y, Cakır I, Yetmis M, Dizdar OS, Baspinar O, Gokay F. Effects of Vitamin D treatment on thyroid autoimmunity. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2016;21:85.
40. Chaudhary S, Dutta D, Kumar M, Saha S, Mondal SA, Kumar A, et al. Vitamin D supplementation reduces thyroid peroxidase antibody levels in patients with autoimmune thyroid disease: An open-labeled randomized controlled trial. Indian journal of endocrinology and metabolism. 20(3):391–8.
41. Behera KK, Saharia GK, Hota D, Sahoo DP, Sethy M, Srinivasan A. Effect of Vitamin D Supplementation on Thyroid Autoimmunity among Subjects of Autoimmune Thyroid Disease in a Coastal Province of India: A Randomized Open-label Trial. Nigerian medical journal : journal of the Nigeria Medical Association. 61(5):237–40.
42. Grove-Laugesen D, Malmstroem S, Ebbehoj E, Riis AL, Watt T, Hansen KW, et al. Effect of 9 months of vitamin D supplementation on arterial stiffness and blood pressure in Graves' disease: a randomized clinical trial. Endocrine. 2019;66(2):386–97.
43. Grove-Laugesen D, Cramon PK, Malmstroem S, Ebbehoj E, Watt T, Hansen KW, et al. Effects of Supplemental Vitamin D on Muscle Performance and Quality of Life in

Graves' Disease: A Randomized Clinical Trial. Thyroid : official journal of the American Thyroid Association. 2020;30(5):661–71.
44. Mei X, Zeng J, Dai W-X, Yang H-L, Li Y, Tang M-W, et al. Prevalence of hyperthyroidism with hypercalcemia in Xindu district and the efficacy of vitamin D3 treatment in these patients: a randomized trial. Annals of palliative medicine. 2021 Sep;10(9):9640–9.
45. Knutsen K v, Madar AA, Brekke M, Meyer HE, Eggemoen ÅR, Mdala I, et al. Effect of Vitamin D on Thyroid Autoimmunity: A Randomized, Double-Blind, Controlled Trial Among Ethnic Minorities. Journal of the Endocrine Society. 2017 May 1;1(5):470–9.
46. Purnamasari D, Djauzi S, Setiati S, Harahap A, Gde Pemayun T, Prihartono J, et al. EFFECTS OF ORAL ALFACALCIDOL ON MATURATION OF DENDRITIC CELLS IN GRAVES' DISEASE PATIENTS: A DOUBLE-BLINDED RANDOMIZED CLINICAL TRIAL. Asian Journal of Pharmaceutical and Clinical Research. 2017 Jun 1;10(6):100.
47. Ucan B, Sahin M, Sayki Arslan M, Colak Bozkurt N, Kizilgul M, Güngünes A, et al. Vitamin D Treatment in Patients with Hashimoto's Thyroiditis may Decrease the Development of Hypothyroidism. International journal for vitamin and nutrition research Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung Journal international de vitaminologie et de nutrition. 2016 Feb;86(1–2):9–17.
48. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of clinical epidemiology. 2011 Apr;64(4):401–6.
49. Saric L, Vucic K, Dragicevic K, Vrdoljak M, Jakus D, Vuka I, et al. Comparison of conference abstracts and full-text publications of randomized controlled trials presented at four consecutive World Congresses of Pain: Reporting quality and agreement of results. European journal of pain (London, England). 2019;23(1):107–16.
50. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health technology assessment (Winchester, England). 2010 Feb;14(8):iii, ix–xi, 1–193.